Akhilesh Pandey

US Patent:

7402659, Jul 22, 2008

Filed:

Feb 7, 2005

Appl. No.:

11/052527

Inventors:

Akhilesh Pandey - Malden MA, US
Katsutoshi Ozaki - Rockville MA, US
Heinz Baumann - Buffalo NY, US
Steven D. Levin - Seattle WA, US
Andrew G. Farr - Seattle WA, US
Warren J. Leonard - Bethesda MA, US
Harvey F. Lodish - Brookline MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA
The Government of the United States of America - Rockville MD
Health Research Inc., Roswell Park Division - Buffalo NY
University of Washington - Seattle WA

International Classification:

C07K 14/475
C12N 15/02
C12P 21/02

US Classification:

530351, 435 691, 4353201, 536 235

Abstract:

The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.

US Patent:

7731953, Jun 8, 2010

Filed:

Jun 13, 2007

Appl. No.:

11/762357

Inventors:

Warren J. Leonard - Bethesda MD, US
Akhilesh Pandey - Pikesville MD, US
Amin Al-Shami - Bethesda MD, US
Rosanne Spolski - Ellicott City MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
Whitehead Institute of Biomedical Research - Cambridge MA

International Classification:

A01N 63/00
C12N 5/071

US Classification:

424 9371, 4353723

Abstract:

Methods are disclosed herein for specifically inducing proliferation of CD4 T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein. The somatic and germ cells of these mice include a disrupted thymic stromal lymphopoietin receptor (TSLP) gene, the disruption being sufficient to inhibit the interaction of TSLP with its receptor, and a disrupted γgene, the disruption being sufficient to reduce signaling through the γ.

US Patent:

20020160949, Oct 31, 2002

Filed:

Jun 28, 2001

Appl. No.:

09/895593

Inventors:

Akhilesh Pandey - Malden MA, US
Katsutoshi Ozaki - Rockville MD, US
Heinz Baumann - Buffalo NY, US
Steven Levin - Seattle WA, US
Andrew Farr - Seattle WA, US
Warren Leonard - Bethesda MD, US
Harvey Lodish - Brookline MA, US

Assignee:

Whitehead Institute for Biomedical

International Classification:

A61K038/17
C07K014/705
C07H021/04
C12P021/02
C12N005/06

US Classification:

514/012000, 530/350000, 536/023500, 435/069100, 435/325000, 435/320100

Abstract:

The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.

US Patent:

20040002112, Jan 1, 2004

Filed:

Oct 31, 2002

Appl. No.:

10/285335

Inventors:

Matthias Mann - Odense, DK
Alexandre Podtelejnikov - Odense, DK
Blagoy Blagoev - Odense, DK
Irina Kratchmarova - Odense, DK
Akhilesh Pandey - Baltimore MD, US

International Classification:

G01N033/53

US Classification:

435/007100

Abstract:

The invention relates to the identification and quantification of proteins differentially expressed during adipogenesis. More specifically, the invention relates to methods for identifying and/or quantitating proteins differentially expressed in one or more specific stage(s) of adipocyte differentiation, using mass spectrometry. The invention also provides those differentially expressed genes as marker genes of adipogenesis. The invention further provides treatment methods for patients suffering from conditions associated with hyper- or hypo-adipogenesis.

US Patent:

20050170459, Aug 4, 2005

Filed:

Feb 7, 2005

Appl. No.:

11/052427

Inventors:

Akhilesh Pandey - Malden MA, US
Katsutoshi Ozaki - Rockville MD, US
Heinz Baumann - Buffalo NY, US
Steven Levin - Seattle WA, US
Andrew Farr - Seattle WA, US
Warren Leonard - Bethesda MD, US
Harvey Lodish - Brookline MA, US

International Classification:

C07H021/04
C07K016/18
C12N005/06

US Classification:

435069100, 435320100, 435326000, 530388100, 536023530

Abstract:

The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.

US Patent:

20050249712, Nov 10, 2005

Filed:

Mar 18, 2005

Appl. No.:

11/084408

Inventors:

Warren Leonard - Bethesda MD, US
Akhilesh Pandey - Pikesville MD, US
Amin Al-Shami - Bethesda MD, US
Rosanne Spolski - Ellicott City MD, US
John Kelly - Hanover NH, US
Andrea Keane-Myers - Bethesda MD, US

International Classification:

A61K045/00
A61K038/18

US Classification:

424093710, 514012000

Abstract:

Methods are disclosed herein for specifically inducing proliferation of CD4 T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein. The somatic and germ cells of these mice include a disrupted thymic stromal lymphopoietin receptor (TSLP) gene, the disruption being sufficient to inhibit the interaction of TSLP with its receptor, and a disrupted γgene, the disruption being sufficient to reduce signaling through the γ. The mice exhibit diminished thymic cellularity. Methods of using these mice for drug screening are also disclosed.

US Patent:

20140051105, Feb 20, 2014

Filed:

Jan 17, 2012

Appl. No.:

13/980005

Inventors:

Bert Vogelstein - Baltimore MD, US
Qing Wang - Parkville MD, US
Akhilesh Pandey - Ellicott city MD, US
Kenneth W. Kinzler - Baltimore MD, US
Nickolas Papadopoulos - Towson MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

G01N 33/68

US Classification:

435 23

Abstract:

Altered protein products resulting from somatic mutations are directly identified and quantified by mass spectrometry. The peptides expressed from normal and mutant alleles are detected by Selected Reaction Monitoring (SRM) of their productions using a triple quadrupole mass spectrometer. As a prototypical example of this approach, we quantify the number and fraction of mutant Ras protein present in cancer cell lines. There were an average of 1.3 million molecules of Ras protein per cell and the ratio of mutant to normal Ras proteins ranged from 0.49 to 5.6. Similarly, we detected and quantified mutant Ras proteins in clinical specimens such as colorectal and pancreatic tumor tissues as well as in pre-malignant pancreatic cyst fluids. These methods are useful for diagnostic applications.